NUVL Quote, Financials, Valuation and Earnings

Glaukos Corp. has a net margin of -- compared to Nuvalent, Inc.'s net margin of -12.16%. Nuvalent, Inc.'s return on equity of -38.24% beat Glaukos Corp.'s return on equity of -11.73%.

Nuvalent, Inc. has a consensus price target of $141.71, signalling upside risk potential of 32.66%. On the other hand Glaukos Corp. has an analysts' consensus of $126.21 which suggests that it could grow by 10.98%. Given that Nuvalent, Inc. has higher upside potential than Glaukos Corp., analysts believe Nuvalent, Inc. is more attractive than Glaukos Corp..

Nuvalent, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Glaukos Corp. has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.203%.

Nuvalent, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Glaukos Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent, Inc. pays -- of its earnings as a dividend. Glaukos Corp. pays out -- of its earnings as a dividend.

Nuvalent, Inc. quarterly revenues are --, which are smaller than Glaukos Corp. quarterly revenues of $133.5M. Nuvalent, Inc.'s net income of -$122.4M is lower than Glaukos Corp.'s net income of -$16.2M. Notably, Nuvalent, Inc.'s price-to-earnings ratio is -- while Glaukos Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent, Inc. is -- versus 13.73x for Glaukos Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Nuvalent, Inc.'s net margin of 21.32%. Nuvalent, Inc.'s return on equity of -38.24% beat Pfizer Inc.'s return on equity of 10.84%.

Nuvalent, Inc. has a consensus price target of $141.71, signalling upside risk potential of 32.66%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 13.22%. Given that Nuvalent, Inc. has higher upside potential than Pfizer Inc., analysts believe Nuvalent, Inc. is more attractive than Pfizer Inc..

Nuvalent, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Nuvalent, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.8% to investors and pays a quarterly dividend of $0.43 per share. Nuvalent, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Nuvalent, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Nuvalent, Inc.'s net income of -$122.4M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Nuvalent, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent, Inc. is -- versus 2.30x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of -- compared to Nuvalent, Inc.'s net margin of -40.15%. Nuvalent, Inc.'s return on equity of -38.24% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

Nuvalent, Inc. has a consensus price target of $141.71, signalling upside risk potential of 32.66%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.13 which suggests that it could grow by 53.69%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Nuvalent, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Nuvalent, Inc..

Nuvalent, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.647%.

Nuvalent, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Nuvalent, Inc. quarterly revenues are --, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Nuvalent, Inc.'s net income of -$122.4M is lower than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Nuvalent, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent, Inc. is -- versus 2.37x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xencor, Inc. has a net margin of -- compared to Nuvalent, Inc.'s net margin of -28.7%. Nuvalent, Inc.'s return on equity of -38.24% beat Xencor, Inc.'s return on equity of -20.07%.

Nuvalent, Inc. has a consensus price target of $141.71, signalling upside risk potential of 32.66%. On the other hand Xencor, Inc. has an analysts' consensus of $28.58 which suggests that it could grow by 91.19%. Given that Xencor, Inc. has higher upside potential than Nuvalent, Inc., analysts believe Xencor, Inc. is more attractive than Nuvalent, Inc..

Nuvalent, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xencor, Inc. has a beta of 0.968, suggesting its less volatile than the S&P 500 by 3.205%.

Nuvalent, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent, Inc. pays -- of its earnings as a dividend. Xencor, Inc. pays out -- of its earnings as a dividend.

Nuvalent, Inc. quarterly revenues are --, which are smaller than Xencor, Inc. quarterly revenues of $21M. Nuvalent, Inc.'s net income of -$122.4M is lower than Xencor, Inc.'s net income of -$6M. Notably, Nuvalent, Inc.'s price-to-earnings ratio is -- while Xencor, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent, Inc. is -- versus 7.36x for Xencor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.